Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.

@article{Strosberg2018HealthRelatedQO,
  title={Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.},
  author={Jonathan R Strosberg and Edward Wolin and Beth A. Chasen and Matthew Kulke and David Bushnell and Martyn Evan Caplin and Richard Paul Baum and Pamela L. Kunz and Timothy James Hobday and Andrew Eugene Hendifar and Kjell Oberg and Maribel Lopera Sierra and Thomas Thevenet and Ines Margalet and Philippe Ruszniewski and Eric P. Krenning},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2018},
  volume={36 25},
  pages={
          2578-2584
        }
}
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related QoL. Methods The NETTER-1 trial is an international phase III study in patients with midgut NETs. Patients were randomly assigned to treatment with 177Lu-Dotatate versus high-dose octreotide. European Organisation for Research and Treatment of Cancer quality-of-life questionnaires QLQ C-30 and G.I… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Quality of life in patients with midgut NET following peptide receptor radionuclide therapy

  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2019
VIEW 3 EXCERPTS
CITES METHODS
HIGHLY INFLUENCED

Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms

  • Advances in radiation oncology
  • 2019
VIEW 2 EXCERPTS
CITES BACKGROUND & RESULTS